VAL-083 Emerging Drug Insight

“VAL-083 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about VAL-083 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the VAL-083 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the VAL-083 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAL-083 market forecast analysis for GBM in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

VAL-083 is a DNA-targeting agent in three distinct biomarker-driven glioblastoma multiforme (GBM) patient populations. VAL-083 can cross the blood-brain barrier (BBB) and has biological and tumor-affecting activity against various cancers, including GBM and ovarian cancer. The drug creates inter-strand DNA cross-links at the N7 position of guanine, one of four main nucleobases in DNA, resulting in double-strand DNA breaks where the MGMT enzyme cannot repair the break, leading to cancer cell death via apoptosis.

The company is currently executing a Phase II clinical developmental trial in first-line treatment in newly diagnosed GBM patients, adjuvant patients who have completed an initial cycle of chemotherapy and radiation therapy, and second-line treatment in recurrent GBM patients.

The company announced that the VAL-083 treatment arm in the global coalition for adaptive research (GCAR) registrational Phase II/III clinical trial for GBM, titled GBM adaptive global innovative learning environment (GBM AGILE), has activated its first European site.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the VAL-083 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on VAL-083 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VAL-083 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VAL-083.
• The report contains forecasted sales of VAL-083 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for VAL-083 in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VAL-083 Analytical Perspective by DelveInsight

• In-depth VAL-083 Market Assessment

This report provides a detailed market assessment of VAL-083 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• VAL-083 Clinical Assessment

The report provides the clinical trials information of VAL-083 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAL-083 dominance.
• Other emerging products for GBM are expected to give tough market competition to VAL-083 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAL-083 in GBM.
• Our in-depth analysis of the forecasted sales data of VAL-083 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VAL-083 in GBM.

Key Questions

• What is the product type, route of administration and mechanism of action of VAL-083?
• What is the clinical trial status of the study related to VAL-083 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAL-083 development?
• What are the key designations that have been granted to VAL-083 for GBM?
• What is the forecasted market scenario of VAL-083 for GBM?
• What are the forecasted sales of VAL-083 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to VAL-083 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?